Articles tagged with Cell Therapies
Five Texas researchers have been honored with the 2025 Edith and Peter O'Donnell Awards for their innovative breakthroughs in small cell lung cancer, lithium-ion battery technology, and galaxy discovery. Lauren Averett Byers is being recognized for her work on novel therapeutic strategies for SCLC, while Caitlin M. Casey is exploring p...
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
Researchers have developed a new generation of cell-penetrating antibodies that can target cancer cells and deliver therapeutic molecules directly into tumor cells. The 3E10 antibody shows great promise for treating cancers with defective DNA repair pathways.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
Researchers found significantly higher levels of p16INK4a in young people with sickle cell disease, indicating accelerated cellular aging. This discovery may lead to new treatments targeting cell aging and improved quality of life for SCD patients.
Research suggests that T-cell receptor repertoire analysis can inform treatment responses and predict efficacy in combination therapies for HCC. Advances in sequencing technologies are refining our understanding of tumor-immune interactions and adaptive immune mechanisms.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Researchers developed an immunotherapeutic platform using lipid-based nanoparticles to deliver therapeutic mRNAs, showing improved efficacy and reduced toxicity. The therapy stimulates the immune system to recognize and eliminate cancer cells, while preserving beneficial immune responses.
Researchers at University of Helsinki and colleagues have mapped the 'hijackome', detailing how SARS-CoV-2 variants exploit specific cellular pathways to spread and evade immune defenses.
Researchers found that a ketogenic diet's beta-hydroxybutyrate (BHB) improves tumor control and survival in mice with diffuse-large B-cell lymphoma. A BHB supplement also boosts CAR T cell expansion and activation in laboratory models of human cancer.
Scientists have created a living cell therapy that can navigate to specific organs using a
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
Researchers at Stanford University have developed a new synthetic receptor, PAGER, that can accommodate a broader range of inputs and produce a more diverse set of outputs. The tool enables control of neuronal activity, immune responses, and therapeutic treatments in lab experiments.
A new study found that gene therapy delandistrogene moxeparvovec significantly extended the median survival of Duchenne muscular dystrophy (DMD) rats to >25 months. Additionally, the treatment elicited statistically significant improvements in cardiac parameters and mobility.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers found impaired PD-1 activity can significantly reduce antibody diversity and quality in memory B cells. This may explain the increased rates of infection reported in patients with cancer receiving checkpoint inhibitor therapy.
Researchers found that treating the Golgi apparatus with hydrogen sulfide creates T-cells that can take more stress, leading to a better chance of controlling tumors. The study suggests sorting T-cells into high and low Golgi groups could be a new therapeutic target.
Researchers at Mass General Brigham developed an AI tool called EVOLVEpro that can engineer proteins to be more stable, precise, and efficient. The tool has shown promise in improving medications used for treating autoimmune diseases, genetic diseases, and cancer.
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Researchers identified three subtypes of fibroblasts in skin cancer: myofibroblast-like RGS5+ CAFs, matrix CAFs (mCAFs), and immunomodulatory CAFs (iCAFs). The distribution of these subtypes varies with tumor aggressiveness. iCAFs produce signaling factors to activate immune cells, while mCAFs prevent T cell invasion.
The conference explores molecular determinants of cancer therapy resistance, a major challenge in the fight against cancer. Researchers discuss new therapeutic approaches and address resistance mechanisms involving tumour cells and the tumour microenvironment.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
Researchers develop non-genetic optoelectronic biointerfaces for targeted stimulation and monitoring of cells, tissues, and organs. The technology offers precise control over biological processes with increased spatial resolution and reduced invasiveness.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
The review explores the impact of extracellular matrix (ECM) geometry on immune cell behavior and treatment efficacy. Specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), create physical barriers that limit immune cell access to tumors.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
Researchers developed a single-cell RNA-sequencing atlas of the Multiple Myeloma immune microenvironment across disease stages. The atlas reveals potential resistance mechanisms and identifies conventional dendritic cells as a targetable population in MM.
The VANCE trial demonstrates that Singapore has the expertise and capabilities to run large-scale global cell therapy trials. The study shows promising results for patients with recurrent or metastatic NPC treated with EBV-CTL therapy, with median survival rates of up to 29.9 months.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Boston Medical Center and Boston University researchers have made a breakthrough in developing cell-based therapy for hypothyroidism. They derived transplantable thyroid follicular epithelial cells from human induced pluripotent stem cells, which can be transplanted into thyroid-deficient animal models.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Rice bioengineers create a mathematical model that challenges long-held assumptions about IL-12's behavior in the body, suggesting repeated doses cause immune cells to hoard IL-12 before it reaches the bloodstream. The findings have significant implications for IL-12 therapy design and may lead to more effective dosing regimens.
A new study introduces a multi-omics-based molecular classification of gastrointestinal stromal tumors, categorizing them into four distinct subtypes. The findings identify key genetic signatures and tumor suppressor genes that influence treatment response, providing a roadmap for personalized therapy strategies.
Scientists at Johns Hopkins Medicine identified 16 genes that breast cancer cells use to survive in the bloodstream, including MUC1, which is already in clinical trials. The research showed that hypoxic cells are able to migrate to higher oxygen levels and form metastasis in the body, leading to a worse prognosis.
A new study suggests that boosting T-regulatory cells may improve the chance of healthy pregnancy and reduce miscarriage risk. Researchers found that treatment with interleukin-2 and antibodies targeting these cells improved pregnancy outcomes in mice, reducing miscarriage rates from 30% to 11%.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
A new guide provides a roadmap for developing cell-penetrating peptide clusters to deliver lifesaving treatments across biological barriers. The clusters could improve patient outcomes dramatically by allowing minimum doses of treatments, reducing toxicity.
Researchers at Terasaki Institute have developed simvastatin-loaded nanoparticles to target adipose tissue inflammation, promoting fat tissue browning and weight loss. The treatment effectively inhibits obesity-related inflammation, controlled white fat production, and demonstrated strong anti-inflammatory effects.
Researchers developed grain-sized soft robots that can transport up to four different drugs, release them in reprogrammable orders and doses, and navigate complex environments inside the human body. The robots' precision functions have the potential to significantly improve therapeutic outcomes while minimizing side effects.
Researchers developed an in vitro model of murine peritoneal macrophage aging to study molecular mechanisms and develop innovative strategies. Chronic treatment with CB3 completely prevented the increase of p21CIP1 and maintained proliferative activity in day 14 macrophages.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Researchers humanize the lupus-derived autoantibody 3E10, preserving its therapeutic efficacy, to create novel cell-penetrating antibodies targeting tumors and RAD51. Humanized variants exhibit faster cell uptake and superior in vivo tumor targeting.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
Researchers found Itaconate stimulates immune cells to produce anti-viral proteins called interferons by blocking an enzyme called SDH, offering a potential therapy for autoimmune and infectious diseases.
A recent clinical trial found that the Nivolumab and Anlotinib combination therapy significantly reduced tumor size in nearly one-third of patients, while most experienced stability in their condition. The treatment also showed improved survival outcomes compared to historical data, with a manageable safety profile.
Researchers have identified a protein called PERM1 that regulates both energy and heart muscle contraction, offering a new therapeutic approach to systolic heart failure. By addressing the underlying problem of weakened heart muscle, PERM1 may help restore cardiac function and improve patient outcomes.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
Research highlights molecular chaperones' role in maintaining tumor suppressor stability and functional integrity. This understanding is crucial for developing targeted therapies for multiple cancers.
A novel nanoparticle therapy targets fat absorption in the small intestine, showing significant potential to prevent diet-induced obesity. The treatment involves inhibiting an enzyme called Sterol O-acyltransferase 2 (SOAT2), which plays a critical role in fat absorption.
A new treatment strategy combining ReCET and semaglutide has been shown to eliminate insulin therapy in 86% of type 2 diabetes patients, improving sensitivity to endogenous insulin. The novel procedure, which employs electroporation, is compliance-free and disease-modifying, addressing ongoing patient adherence issues.